arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

NRX Pharmaceuticals, Inc.

NRXP Health Care Biotechnology: Pharmaceutical Preparations
$2.49
▼ -5.3% Today
as of Oct 23, 16:50 ET
Last 30 days -28.65% Sep 14 → Oct 23
$2.31 $2.63 $2.95 $3.26 $3.58 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$2.36
High
$2.50
Low
$2.24
Volume
$829,712
Avg Vol
$943,396
Mkt Cap
$123M
P/E (TTM)
—
Beta
—
52w High
$5.05
52w Low
$1.62
Div Yield
—
Shares Out
$43M

Recent Press Releases & News last 60 days · 8 items

Oct 19 · 12:30 PR GlobeNewswire
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
Oct 15 · 12:27 PR GlobeNewswire
NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
Sep 30 · 11:00 PR GlobeNewswire
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
▸ Show all 8 press releases & news Free account →

NRXP earnings at a glance

The options market is pricing a move of about ±36.2% after the report, a range of roughly $1.59 to $3.39 from today's $2.49. Over its last 2 reports the stock rose the next day 2 times and fell 0, moving ±4.0% on average; after the most recent report on May 15, 2026 it moved +2.2%. That means options currently expect more movement than NRXP has typically delivered. NRXP beat the consensus EPS estimate in 1 of its last 2 reported quarters. Implied volatility is currently 289%. The share price of $2.49 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$1.62
$5.05
25% of range
Avg surprise (last 2)
-21.8%
Avg reaction (last 2)
+4.0%
100% positive
Latest IV / EM
289%
EM ±36.2% · $3 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.66$-1.25$-0.85$-0.45$-0.04 Actual $-1.66Actual $-0.12Actual $-0.07Actual $-0.74Actual $-0.34Actual $-0.98Actual $-0.18Est $-0.11Actual $-0.04Est $-0.05 MarJunSepMarMar/2025Jun/2025Sep/2025Mar/2026
Revenue vs Net Income Revenue Net income
$-18M$-13M$-8M$-4M$1M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Fri May 15, 2026Mar/2026 $-0.04 $-0.05 +20.0% +88.2% +2.2% earnings
Fri Nov 14, 2025Sep/2025 $-0.18 $-0.11 -63.6% — — earnings
Mon Aug 18, 2025Jun/2025 $-0.98 — — — — earnings
Thu May 15, 2025Mar/2025 $-0.34 — — — +5.7% earnings
Sun Mar 31, 2024Mar 2024 $-0.74 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.07 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.12 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.66 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$1M$1M—$242,000$0$0—$0
Cost of revenue$675,000$631,000—$97,000$0$0—$0
Gross profit————————
Operating income$-7M$-5M—$-4M$-4M$-4M—$-3M
Net income$-17M$-1M—$-6M$-18M$-6M—$-2M
EPS (diluted)————————

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$27M$7M$8M$7M$3M$6M$1M$2M
Inventory————————
Total current assets$29M$7M$9M$12M$5M$7M$3M$4M
Total assets$34M$12M$13M$15M$5M$8M$4M$4M
Long-term debt————————
Total liabilities$34M$26M$29M$41M$40M$33M$27M$23M
Total equity$-170,000$-14M$-16M$-26M$-36M$-25M$-23M$-19M

Implied volatility — last 90 days

65%401%736%1072%1408% Jun 07 — IV 205% · EM ±28.4%Jun 08 — IV 179% · EM ±23.6%Jun 09 — IV 300% · EM ±37.6%Jun 10 — IV 585% · EM ±69.1%Jun 11 — IV 577% · EM ±63.8%Jun 12 — IV 375% · EM ±38.3%Jun 15 — IV 398% · EM ±28.8%Jun 16 — IV 501% · EM ±29.6%Jun 17 — IV 1200% · EM ±50.1%Jun 19 — IV 319% · EM ±70.5%Jun 22 — IV 200% · EM ±41.7%Jun 23 — IV 428% · EM ±87.5%Jun 24 — IV 185% · EM ±37.1%Jun 25 — IV 190% · EM ±37.2%Jun 26 — IV 250% · EM ±47.8%Jun 29 — IV 236% · EM ±41.9%Jun 30 — IV 366% · EM ±63.0%Jul 01 — IV 357% · EM ±59.6%Jul 02 — IV 447% · EM ±72.3%Jul 03 — IV 463% · EM ±72.4%Jul 06 — IV 384% · EM ±53.2%Jul 07 — IV 418% · EM ±55.2%Jul 08 — IV 510% · EM ±63.9%Jul 09 — IV 475% · EM ±56.1%Jul 10 — IV 302% · EM ±33.4%Jul 13 — IV 379% · EM ±31.6%Jul 14 — IV 407% · EM ±29.4%Jul 15 — IV 503% · EM ±29.7%Jul 16 — IV 802% · EM ±33.5%Jul 20 — IV 132% · EM ±31.1%Jul 21 — IV 127% · EM ±29.5%Jul 22 — IV 108% · EM ±24.7%Jul 23 — IV 65% · EM ±14.7%Jul 24 — IV 338% · EM ±74.7%Jul 27 — IV 343% · EM ±71.6%Jul 28 — IV 394% · EM ±80.5%Jul 29 — IV 232% · EM ±46.4%Jul 30 — IV 206% · EM ±40.3%Jul 31 — IV 315% · EM ±60.3%Aug 03 — IV 269% · EM ±47.7%Aug 04 — IV 343% · EM ±59.0%Aug 05 — IV 289% · EM ±48.3%Aug 06 — IV 300% · EM ±48.5%Aug 07 — IV 431% · EM ±67.4%Aug 10 — IV 355% · EM ±49.1%Aug 11 — IV 466% · EM ±61.6%Aug 12 — IV 451% · EM ±56.5%Aug 13 — IV 659% · EM ±77.8%Aug 14 — IV 631% · EM ±69.7%Aug 17 — IV 611% · EM ±51.0%Aug 19 — IV 1017% · EM ±60.1%Aug 20 — IV 1408% · EM ±58.8%Aug 24 — IV 279% · EM ±58.3%Aug 25 — IV 227% · EM ±46.5%Aug 26 — IV 281% · EM ±56.4%Aug 27 — IV 282% · EM ±55.2%Aug 28 — IV 260% · EM ±49.8%Aug 31 — IV 243% · EM ±43.1%Sep 01 — IV 312% · EM ±53.8%Sep 02 — IV 342% · EM ±57.2%Sep 03 — IV 306% · EM ±49.6%Sep 04 — IV 375% · EM ±58.6%Sep 07 — IV 424% · EM ±58.7%Sep 08 — IV 360% · EM ±47.6%Sep 09 — IV 402% · EM ±50.4%Sep 10 — IV 448% · EM ±52.9%Sep 11 — IV 453% · EM ±50.0%Sep 14 — IV 772% · EM ±64.5%Sep 15 — IV 628% · EM ±45.5%Sep 16 — IV 731% · EM ±43.2%Sep 17 — IV 1165% · EM ±48.7%Sep 21 — IV 296% · EM ±61.8%Sep 22 — IV 272% · EM ±55.6%Sep 23 — IV 237% · EM ±47.5%Sep 24 — IV 186% · EM ±36.4%Sep 25 — IV 230% · EM ±44.1%Sep 29 — IV 219% · EM ±37.8%Oct 01 — IV 234% · EM ±37.8%Oct 02 — IV 250% · EM ±39.0%Oct 06 — IV 280% · EM ±36.9%Oct 07 — IV 289% · EM ±36.2%

Sector peers

CRBP
Corbus Pharmaceuticals Holdings, Inc.
$123M $4.05-5.5%
SPRB
Spruce Biosciences, Inc.
$129M $45.15+5.7%
AARD
Aardvark Therapeutics, Inc.
$115M $1.39-68.5%
LIXT
Lixte Biotechnology Holdings, Inc.
$115M $7.21+75.8%
PMVP
PMV Pharmaceuticals, Inc.
$132M $1.27-6.6%
GNLX
Genelux Corporation
$114M $2.00-3.4%

NRXP earnings FAQ

What is NRXP's expected move for earnings?

Options currently price a move of about ±36.2%, or $0.90 per share either way from $2.49.

How does NRXP stock usually react to earnings?

Across the last 2 reports the average next-day move was ±4.0%, up 2 times and down 0 times.

What is NRXP's implied volatility?

NRXP's at-the-money implied volatility is about 289% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in